{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:21:16Z","timestamp":1790270476900,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.vaccine.2012.01.088","type":"journal-article","created":{"date-parts":[[2012,2,10]],"date-time":"2012-02-10T18:02:55Z","timestamp":1328896975000},"page":"3126-3135","source":"Crossref","is-referenced-by-count":146,"title":["Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice"],"prefix":"10.1016","volume":"30","author":[{"given":"Najoua","family":"Dendouga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Fochesato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Lockman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Mossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra L.","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2012.01.088_bib0005","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/jama.2010.1983","article-title":"Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease","volume":"305","author":"Tseng","year":"2011","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.vaccine.2012.01.088_bib0010","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.01.088_bib0015","first-page":"9","article-title":"The nature of Herpes Zoster: a long-term study and a new hypothesis","volume":"58","author":"Hope-Simpson","year":"1965","journal-title":"Proc R Soc Med"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2012.01.088_bib0020","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1386-6532(10)70002-0","article-title":"Advances in the understanding of the pathogenesis and epidemiology of herpes zoster","volume":"48","author":"Gershon","year":"2010","journal-title":"J Clin Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2012.01.088_bib0025","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1086\/421277","article-title":"Development of virus-specific CD4+ T cells on reexposure to varicella-zoster virus","volume":"190","author":"Vossen","year":"2004","journal-title":"J Infect Dis"},{"issue":"19","key":"10.1016\/j.vaccine.2012.01.088_bib0030","doi-asserted-by":"crossref","first-page":"9772","DOI":"10.1128\/JVI.00564-06","article-title":"Persistent high frequencies of varicella-zoster virus ORF4 protein-specific CD4+ T cells after primary infection","volume":"80","author":"Jones","year":"2006","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2012.01.088_bib0035","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1086\/315347","article-title":"Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression","volume":"181","author":"Asanuma","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.01.088_bib0040","first-page":"341","article-title":"T cell-mediated immunity","volume":"342","author":"Weinberg","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2012.01.088_bib0045","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1086\/522123","article-title":"Humoral and cellular immunity to varicella-zoster virus: an overview","volume":"197","author":"Arvin","year":"2008","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2012.01.088_bib0050","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.arr.2010.10.007","article-title":"Dysregulation of human Toll-like receptor function in aging","volume":"10","author":"Shaw","year":"2011","journal-title":"Ageing Res Rev"},{"issue":"4","key":"10.1016\/j.vaccine.2012.01.088_bib0055","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.coi.2010.05.003","article-title":"Aging of the innate immune system","volume":"22","author":"Shaw","year":"2010","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2012.01.088_bib0060","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ni1033","article-title":"Age-related changes in lymphocyte development and function","volume":"5","author":"Linton","year":"2004","journal-title":"Nat Immunol"},{"issue":"22","key":"10.1016\/j.vaccine.2012.01.088_bib0065","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1056\/NEJMp058091","article-title":"Aging, immunity, and the varicella-zoster virus","volume":"352","author":"Arvin","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2012.01.088_bib0070","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2012.01.088_bib0075","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa013441","article-title":"Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants","volume":"347","author":"Hata","year":"2002","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2012.01.088_bib0080","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/653605","article-title":"Zoster vaccine: current status and future prospects","volume":"51","author":"Oxman","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2012.01.088_bib0085","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2012.01.088_bib0090","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/14760584.6.5.723","article-title":"GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives","volume":"6","author":"Gar\u00e7on","year":"2007","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2012.01.088_bib0095","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems","volume":"10","author":"Gar\u00e7on","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2012.01.088_bib0100","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1128\/JVI.00913-08","article-title":"Deletion of the first cysteine-rich region of the varicella-zoster virus glycoprotein E ectodomain abolishes the gE and gI interaction and differentially affects cell\u2013cell spread and viral entry","volume":"83","author":"Berarducci","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2012.01.088_bib0105","series-title":"Fields Virology","first-page":"2773","article-title":"Varicella-zoster virus replication, pathogenesis and management","author":"Cohen","year":"2007"},{"key":"10.1016\/j.vaccine.2012.01.088_bib0110","series-title":"Structure\u2013function relationships of human pathogenic viruses","first-page":"195","article-title":"The predominant varicella-zoster virus gE and gI glycoprotein complex","author":"Grose","year":"2002"},{"issue":"2","key":"10.1016\/j.vaccine.2012.01.088_bib0115","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1006\/viro.2002.1556","article-title":"The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells","volume":"304","author":"Mo","year":"2002","journal-title":"Virology"},{"issue":"11","key":"10.1016\/j.vaccine.2012.01.088_bib0120","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1128\/JVI.71.11.8279-8288.1997","article-title":"Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking","volume":"71","author":"Mallory","year":"1997","journal-title":"J Virol"},{"issue":"19","key":"10.1016\/j.vaccine.2012.01.088_bib0125","doi-asserted-by":"crossref","first-page":"9481","DOI":"10.1128\/JVI.00533-06","article-title":"Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection","volume":"80","author":"Berarducci","year":"2006","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2012.01.088_bib0130","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1073\/pnas.0912373107","article-title":"Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection","volume":"107","author":"Berarducci","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.vaccine.2012.01.088_bib0135","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/jmv.1890460202","article-title":"Distribution of varicella-zoster virus gpI and gpII and corresponding genome sequences in the skin","volume":"46","author":"Nikkels","year":"1995","journal-title":"J Med Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2012.01.088_bib0140","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/vim.1991.4.151","article-title":"Human T cells recognize multiple epitopes of an immediate early\/tegument protein (IE62) and glycoprotein I of varicella zoster virus","volume":"4","author":"Bergen","year":"1991","journal-title":"Viral Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2012.01.088_bib0145","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1006\/viro.1995.0064","article-title":"Identification of immunodominant regions and linear B cell epitopes of the gE envelope protein of varicella-zoster virus","volume":"214","author":"Fowler","year":"1995","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.vaccine.2012.01.088_bib0150","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1365-2249.2008.03633.x","article-title":"Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors","volume":"152","author":"Malavige","year":"2008","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2012.01.088_bib0155","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s007050050081","article-title":"Characterization of neutralizing domains on varicella-zoster virus glycoprotein E defined by monoclonal antibodies","volume":"142","author":"Wu","year":"1997","journal-title":"Arch Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2012.01.088_bib0160","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4049\/jimmunol.146.1.257","article-title":"Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype","volume":"146","author":"Arvin","year":"1991","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2012.01.088_bib0165","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/infdis\/162.5.1049","article-title":"The immunogenicity of the Oka\/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content","volume":"162","author":"Bergen","year":"1990","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2012.01.088_bib0170","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1039\/c003798b","article-title":"Systematic analysis of the IgG antibody immune response against varicella zoster virus (VZV) using a self-assembled protein microarray","volume":"6","author":"Ceroni","year":"2010","journal-title":"Mol Biosyst"},{"issue":"5","key":"10.1016\/j.vaccine.2012.01.088_bib0175","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/infdis\/165.5.852","article-title":"Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine","volume":"165","author":"Sharp","year":"1992","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2012.01.088_bib0180","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/(SICI)1096-9071(199709)53:1<63::AID-JMV11>3.0.CO;2-Y","article-title":"Neutralizing antibody responses induced by varicella-zoster virus gE and gB glycoproteins following infection, reactivation or immunization","volume":"53","author":"Haumont","year":"1997","journal-title":"J Med Virol"},{"issue":"14","key":"10.1016\/j.vaccine.2012.01.088_bib0185","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/0264-410X(94)00073-V","article-title":"Boosting immune response with a candidate varicella-zoster virus glycoprotein subunit vaccine","volume":"13","author":"Vafai","year":"1995","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2012.01.088_bib0190","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1086\/515638","article-title":"Recombinant varicella-zoster virus glycoproteins E and I: immunologic responses and clearance of virus in a guinea pig model of chronic uveitis","volume":"178","author":"Kimura","year":"1998","journal-title":"J Infect Dis"},{"issue":"Pt 6","key":"10.1016\/j.vaccine.2012.01.088_bib0195","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1099\/0022-1317-72-6-1445","article-title":"Immunogenicity in mice of varicella-zoster virus glycoprotein I expressed by a vaccinia virus-varicella-zoster virus recombinant","volume":"72","author":"Ludv\u00edkov\u00e1","year":"1991","journal-title":"J Gen Virol"},{"issue":"11\u201312","key":"10.1016\/j.vaccine.2012.01.088_bib0200","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0264-410X(01)00486-8","article-title":"Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation","volume":"20","author":"Jacquet","year":"2002","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2012.01.088_bib0205","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0264-410X(99)00428-4","article-title":"Immunization with a DNA expression vector encoding the varicella zoster virus glycoprotein E (gE) gene via intramuscular and subcutaneous routes","volume":"18","author":"Hasan","year":"2000","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2012.01.088_bib0210","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-1702(95)01270-2","article-title":"Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells","volume":"40","author":"Haumont","year":"1996","journal-title":"Virus Res"},{"issue":"Pt 4","key":"10.1016\/j.vaccine.2012.01.088_bib0215","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1099\/0022-1317-73-4-811","article-title":"Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62","volume":"73","author":"Lowry","year":"1992","journal-title":"J Gen Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2012.01.088_bib0220","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/0264-410X(93)90382-8","article-title":"Antigenicity of a candidate varicella-zoster virus glycoprotein subunit vaccine","volume":"11","author":"Vafai","year":"1993","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.01.088_bib0225","first-page":"309","article-title":"Simian varicella virus pathogenesis","volume":"342","author":"Mahalingam","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2012.01.088_bib0230","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/CMR.00031-09","article-title":"Impact of varicella vaccine on varicella-zoster virus dynamics","volume":"23","author":"Schmid","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"8","key":"10.1016\/j.vaccine.2012.01.088_bib0235","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.vaccine.2007.12.018","article-title":"Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen","volume":"26","author":"Mettens","year":"2008","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2012.01.088_bib0240","doi-asserted-by":"crossref","first-page":"e14090","DOI":"10.1371\/journal.pone.0014090","article-title":"Safety of the malaria vaccine candidate, RTS,S\/AS01E in 5 to 17 month old Kenyan and Tanzanian Children","volume":"5","author":"Lusingu","year":"2010","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.vaccine.2012.01.088_bib0245","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1026403724413","article-title":"Immunofluorescence analysis of T-cell responses in health and disease","volume":"20","author":"Maecker","year":"2000","journal-title":"J Clin Immunol"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2012.01.088_bib0250","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0022-1759(01)00416-1","article-title":"Use of overlapping peptide mixtures as antigens for cytokine flow cytometry","volume":"255","author":"Maecker","year":"2001","journal-title":"J Immunol Methods"},{"issue":"7198","key":"10.1016\/j.vaccine.2012.01.088_bib0255","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nature06939","article-title":"Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants","volume":"453","author":"Eisenbarth","year":"2008","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.vaccine.2012.01.088_bib0260","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.4049\/jimmunol.181.6.3755","article-title":"Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome","volume":"181","author":"Kool","year":"2008","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2012.01.088_bib0265","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.coi.2009.01.004","article-title":"Mechanism of action of clinically approved adjuvants","volume":"21","author":"Lambrecht","year":"2009","journal-title":"Curr Opin Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2012.01.088_bib0270","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based Adjuvant System, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J Immunol"},{"issue":"20","key":"10.1016\/j.vaccine.2012.01.088_bib0275","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s00018-008-8228-6","article-title":"Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant","volume":"65","author":"Casella","year":"2008","journal-title":"Cell Mol Life Sci"},{"issue":"4 Suppl.","key":"10.1016\/j.vaccine.2012.01.088_bib0280","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1038\/nm1210","article-title":"Targeting the innate immune response with improved vaccine adjuvants","volume":"11","author":"Pashine","year":"2005","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.vaccine.2012.01.088_bib0285","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrmicro1681","article-title":"The perfect mix: recent progress in adjuvant research","volume":"5","author":"Guy","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2012.01.088_bib0290","first-page":"1","article-title":"Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Centers for Disease Control and Prevention","year":"2008","journal-title":"Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2012.01.088_bib0295","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1046\/j.1365-2249.2003.02061.x","article-title":"Local immune responses and systemic cytokine responses in zoster: relationship to the development of postherpetic neuralgia","volume":"131","author":"Zak-Prelich","year":"2003","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2012.01.088_bib0300","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1365-2249.1994.tb06618.x","article-title":"Cytokine production in varicella zoster virus-stimulated limiting dilution lymphocyte cultures","volume":"98","author":"Zhang","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2012.01.088_bib0305","series-title":"Human herpesviruses: biology, therapy, and immunoprophylaxis","article-title":"VZV: immunobiology and host response","author":"Arvin","year":"2007"},{"issue":"1","key":"10.1016\/j.vaccine.2012.01.088_bib0310","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1086\/375828","article-title":"Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination","volume":"188","author":"Frey","year":"2003","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2012.01.088_bib0315","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1002\/eji.200737648","article-title":"Phenotypic analysis of human CD4+ T cells specific for immediate-early 63 protein of varicella-zoster virus","volume":"37","author":"Jones","year":"2007","journal-title":"Eur J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2012.01.088_bib0320","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1086\/511274","article-title":"Rapid effector function of varicella-zoster virus glycoprotein I-specific CD4+ T cells many decades after primary infection","volume":"195","author":"Malavige","year":"2007","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2012.01.088_bib0325","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10875-010-9499-x","article-title":"Gain and loss of T cell subsets in old age\u2014age-related reshaping of the T cell repertoire","volume":"31","author":"Arnold","year":"2011","journal-title":"J Clin Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2012.01.088_bib0330","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.it.2009.05.002","article-title":"Vaccination in the elderly: an immunological perspective","volume":"30","author":"Chen","year":"2009","journal-title":"Trends Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2012.01.088_bib0335","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1086\/529197","article-title":"Biology of immune responses to vaccines in elderly persons","volume":"46","author":"Weinberger","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2012.01.088_bib0340","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1586\/14760584.7.4.467","article-title":"Age-related decline in immunity: implications for vaccine responsiveness","volume":"7","author":"Kumar","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2012.01.088_bib0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399407000221","article-title":"Age-related changes in immunity: implications for vaccination in the elderly","volume":"9","author":"Kovaiou","year":"2007","journal-title":"Expert Rev Mol Med"},{"issue":"25","key":"10.1016\/j.vaccine.2012.01.088_bib0350","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1056\/NEJMoa0908535","article-title":"A novel influenza A (H1N1) vaccine in various age groups","volume":"361","author":"Zhu","year":"2009","journal-title":"N Engl J Med"},{"issue":"42","key":"10.1016\/j.vaccine.2012.01.088_bib0355","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1016\/j.vaccine.2009.07.038","article-title":"A dose-ranging study of a subunit respiratory syncytial virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults \u226565 years of age","volume":"27","author":"Langley","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2012.01.088_bib0360","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1006\/mpat.1993.1064","article-title":"A mouse model for varicella-zoster virus latency","volume":"15","author":"Wroblewska","year":"1993","journal-title":"Microb Pathog"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12001612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12001612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T15:15:33Z","timestamp":1686755733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12001612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":72,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0264410X12001612"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.01.088","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}